Trevi Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. on September 11, 2020, regarding an event reported on September 8, 2020. The Company is a Delaware corporation with its principal executive offices in New Haven, Connecticut, and its common stock trades on The Nasdaq Stock Market under the symbol "TRVI". The Company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event and does not contain financial statements or performance data.
Material Changes
The material change disclosed in this filing is the departure of a senior executive. Yann Mazabraud notified the Company of his intention to resign from his positions as Chief Commercial Officer and Head of International. His resignation is effective October 3, 2020.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the operational impact of the executive departure. No unusual items or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Yann Mazabraud is resigning as Chief Commercial Officer and Head of International.
- The resignation is effective October 3, 2020.
- The Company has not disclosed a replacement for these roles in this filing.
- No financial performance data is included in this specific report.